ADCT website. Atopic Dermatitis Control Tool. Updated October 2020. Accessed February 12, 2021. www.adcontroltool.com
American Academy of Dermatology Association website. Atopic dermatitis clinical guideline. Updated 2021. Accessed May 17, 2021. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
American Academy of Dermatology Association website. Homepage. Updated 2021. Accessed May 17, 2021. http://www.aad.org.
Asgari MM, Tsai AL, Avalos L, et al. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156:1-8.
Barker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol. 2007;127:564-567.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-139.
Bieber T, D’Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017;139:S58-S64.
Blauvelt A, Guttman E, Hussain I, et al. Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE). J Am Acad Dermatol. 2020;83(6 Suppl): Abstract 15108.
Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120:10-22.
Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76.
Brunner PM, Pavel AB, Khattri S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol. 2019;143:142-154.
Brunner PM, Suárez-Fariñas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2018;7:8707.
Callewaert C, Nakatsuji T, Knight R, et al. IL-4Ra Blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol. 2020;140:191-202.
Cevikbas F, Wang X, Akiyama T, et al. A Sensory neuron-expressed interleukin-31 receptor mediates t helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133:448-460.
ClinicalTrials.gov. Dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic dermatitis. Updated June 30, 2020. Accessed May 17, 2021. https://clinicaltrials.gov/ct2/show/NCT03725722
Cury Martins J, Martins C, Aoki V, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015(7):CD009864.
Czarnowicki T, Dohlman AB, Malik K, et al. Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial. Ann Allergy Asthma Immunol. 2018;120:631-640.e11.
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143:1-11.
Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol. 2015;136:208-211.
De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773-86.e867.
Dhingra N, Gulati N, Guttman-Yassky E. Mechanisms of contact sensitization offer insights into the role of barrier defects vs. intrinsic immune abnormalities as drivers of atopic dermatitis. J Invest Dermatol. 2013;133:2311-2314
Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol. 2014;134:2071-2074.
Draelos ZD, Ports WC, Vlahos B, et al. Skin permeation and penetration of crisaborole when coapplied with emollients. J Am Acad Dermatol. 2020;83:1801-1803.
DUPIXENT® (dupilumab) [prescribing information]. Regeneron Pharmaceuticals, Inc; Approved 2017. Revised May 2020.
Ferrandiz C, de la Cueva Dobao P, Simpson EL, et al. Dupilumab in moderate-to-severe atopic dermatitis: pooled efficacy results from two identically designed randomized phase 3 trials (SOLO 1 & 2). SKIN J Cutaneous Med. 2017;1:s38.
Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20:5424.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344-1354.
Gooderham M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: Phase 2 proof-of-concept study. Presented at: the European Academy of Dermatology and Venereology (EADV) 2020; October 29-31, 2020; Virtual. Abstract FC08.07.
Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155-172.
Guttman-Yassky E, Blauvelt, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156:411-420.
Guttman-Yassky E, et al. Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: Results from two pivotal phase III, randomized, double-blinded, placebo-controlled studies (Measure Up 1 and Measure Up 2). Presented at: the European Academy of Dermatology and Venereology (EADV) 2020; October 29-31, 2020; Virtual. Abstract D3T03.4B.
Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124:1235-1244.e58.
Guttman-Yassky E. The disease burden of atopic dermatitis: the unmet need for new therapies in patients with moderate-to severe and/or resistant AD-the rationale and necessity for intervening in the atopic march and mitigating the risk of co-morbid conditions. Presented at: the 2nd Inflammatory Skin Disease Summit; November 16-19, 2016; New York, NY. Presentation.
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293-1300.
Hönzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and ß-Defensins in Filaggrin-Deficient Skin Equivalents. J Invest Dermatol. 2016;136:631-639.
Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008;128:2248-2258.
Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Investig. 2011;121:3375-3383.
Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-tosevere atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142:1121-1130.
Kabashima K, Matsumura T, Komazaki H, et al; for the Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141-150.
Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126:332-337.
Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145:572-582.
Kim BS, Howell MD, Sun K, et al; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145:572-582.
Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850-859.
Landis M, et al. A Phase 2b study to evaluate the efficacy and safety of the topical TYK2/JAK1 inhibitor brepocitinib for mild-to-moderate atopic dermatitis. Presented at: the European Academy of Dermatology and Venereology (EADV) 2020; October 29-31, 2020; Virtual. Late-breaking abstract D1T03.4D.
Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-779.
Myles IA, Castillo CR, Barbian KD, et al. Therapeutic responses to Roseomonas mucosa in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair. Sci Transl Med. 2020;12(560):eaaz8631.
Nakagawa H, Iizuka H, Nemoto O, et al. Safety, tolerability and efficacy of repeated intravenous infusions of a fully human anti-OX40 monoclonal antibody (KHK4083) in patients with moderate to severe atopic dermatitis. Presented at: the European Academy of Dermatology and Venereology; September 12-16, 2018; Paris, France. Abstract P0252.
Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82:823-831.
Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47:114-120
Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 144:1575-1583.
Nemoto O, Furue m, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296-304.
Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21:239-260.
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135:324-336.
Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092-1102.
Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233:344-357.
Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51:329-337.
Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:309-321.
Ouedraogo ZG, Fouache A, Trousson A, et al. Role of the liver X receptors in skin physiology: Putative pharmacological targets in human diseases. Chem Phys Lipids. 2017;207(Pt B):59-68.
Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83:375-381.
Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:26-35.
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83:1282-1293. Erratum in: J Am Acad Dermatol. 2021 Jan;84(1):230. PMID: 32574587.
Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021;84:632-638.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441-446.
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Presented at: the European Academy of Dermatology and Venereology (EADV) 2020; October 29-31, 2020; Virtual. Presentation FC08.08.
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2019;36:367-376.
Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80:89-98.e3.
Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178:2229-2240. Erratum in: J Immunol. 2007;178:7487.
Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21:275-284.
Sidbury R, Davis DM, Cohen, DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327-349.
Silverberg JI, Eckert L, Ardeleanu M, et al. Dupilumab treatment induces rapid clinical improvement of itch in patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2018;79(2 Suppl 1): Abstract 7414.
Silverberg JI, et al. Long-term efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis enrolled in the phase 3 long-term extension study BREEZE-AD3. Presented at: the European Academy of Dermatology and Venereology (EADV) 2020; October 29-31, 2020; Virtual. Presentation D3T03.4A.
Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:863-873.
Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82:1328-1336.
Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. Allergy. 2015;70:1300-1308.
Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19:15.
Simpson E, et al. Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: Results from two 52-week Phase 3 trials (ECZTRA 1 and ECZTRA 2). Presented at: the 2020 American Academy of Dermatology Virtual Meeting Experience (AAD VMX); June 12-14, 2020. Presentation.
Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77:623-633.
Simpson EL, et al. JAK inhibition for atopic dermatitis. Presented at: the 2020 American Academy of Dermatology Virtual Meeting Experience (AAD VMX); June 12-14, 2020. Presentation.
Simpson EL, Fujita H, Arima K, et al. Dupilumab decreases blood biomarkers in adolescents with moderate-to-severe atopic dermatitis: data from a phase 3 trial (LIBERTY AD ADOL). J of Skin. 2020;4:s49.
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44-56.
Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80:1013-1021.
Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127:954-64.e644.
Thaçi D, Deleuran M, Bissonnette R, et al. Favorable safety and sustained efficacy with long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE). Presented at: the Virtual & Live Revolutionizing Atopic Dermatitis Conference 2020 (RAD) December 5-7, 2020; Chicago, IL. Presentation.
Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137:603-613.
Ungar B, Pavel AB, Robson PM, et al. A preliminary 18F-FDG-PET/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2020;8:3500-3506.
Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
Weidinger S, et al. Efficacy and safety of tralokinumab with concomitant topical corticosteroid in adult patients with moderate-to-severe atopic dermatitis: Results from the 32-week Phase 3 ECZTRA 3 trial. Presented at: the 2020 American Academy of Dermatology Virtual Meeting Experience (AAD VMX); June 12-14, 2020. Presentation.
Welten SP, Melief CJ, Arens R. The distinct role of T cell costimulation in antiviral immunity. Curr Opin Virol. 2013;3:475-482.
Wollenberg A, Boguniewicz M, Travers J, et al. Efficacy of baricitinib in patients with atopic dermatitis and atopic comorbidities: results of pooled data from 2 phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2). Presented at: the American Academy of Allergy, Asthma & Immunology (AAAAI) Meeting. March 13-16, 2020; Philadelphia, PA. Poster 610.
Woźniak M, Kaczmarek-Skamira E, Romańska-Gocka K, et al. The prevalence of mutations in the gene encoding filaggrin in the population of Polish patients with atopic dermatitis. Postepy Dermatol Alergol. 2016;33:128-133.
Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78:733-740.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Lawrence F. Eichenfield, MD

Professor of Dermatology and Pediatrics
Vice Chair
Department of Dermatology
Chief
Pediatric and Adolescent Dermatology
University of California, San Diego
Rady Children's Hospital, San Diego
San Diego, California

Disclosures

Disclosure: Lawrence F. Eichenfield, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Almirall; Dermavant; Dermira Inc.; Eli Lilly and Company; Forte Biosciences; Galderma Laboratories, L.P.; Incyte Corporation; LEO Pharma; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme
Received grants for clinical research from: AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; Ortho Dermatologics; Sanofi Genzyme
Owns stock, stock options, or bonds from: Forte Biosciences
Other: Asana Biosciences, LLC; Glenmark

Jonathan I. Silverberg, MD, PhD, MPH

Associate Professor
Department of Dermatology
Director
Clinical Research
Director
Patch Testing
The George Washington University School
of Medicine and Health Sciences
Washington, DC

Disclosures

Disclosure: Jonathan I. Silverberg, MD, PhD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AFYX; Arena Pharmaceuticals, Inc.; Asana Biosciences, LLC; BioMX; Bluefin; Bodewell; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; Dermira Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Kiniksa; LEO Pharma; Luna; Menlo; Novartis Pharmaceuticals Corporation; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc; Sanofi
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Received grants for clinical research from: Galderma Laboratories, L.P.; Pfizer Inc.

Emma Guttman-Yassky, MD, PhD

Waldman Professor and System Chair, Dermatology
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York
President
International Eczema Council
Chicago, Illinois

Disclosures

Disclosure: Emma Guttman-Yassky, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Aditum Bio; Almirall; Amgen Inc.; Asana Biosciences, LLC; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Celgene Corporation; Concert; DBV; Dermira Inc.; DS Biopharma; Eli Lilly and Company; EMD Serono; Escalier; Galderma Laboratories, L.P.; Ichnos Sciences; Incyte Kyowa Kirin; LEO Pharma; Mitsubishi Tanabe; Pandion Therapeutics; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; Sienna Biopharma; Target PharmaSolutions; Union Therapeutics
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Almirall; Amgen Inc.; AnaptysBio; Asana Biosciences, LLC; Boehringer-Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; DS Biopharma; Eli Lilly and Company; Galderma Laboratories, L.P.; Ichnos Sciences; Innovaderm; Janssen Pharmaceuticals; Kiniksa; Kyowa Kirin; LEO Pharma; Novan; Pfizer Inc.; Ralexar; Regeneron Pharmaceuticals, Inc.; Sienna Biopharma; UCB Pharma, Inc.; Union Therapeutics

Eric L. Simpson, MD, MCR

Professor of Dermatology
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Eric L. Simpson, MD, MCR, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Arena Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Collective Acumen LLC; Eli Lilly and Company; Forte Bio; Incyte Corporation; Janssen Pharmaceuticals; Kyowa Hakko Kirin; LEO Pharma; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Pfizer Inc.; Pierre Fabre Dermo Cosmetique; Regeneron Pharmaceuticals, Inc.; Roivant; Sanofi; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; Eli Lilly and Company; Kyowa Hakko Kirin; LEO Pharma; Merck; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi; Tioga; Vanda

Editor

Marinella Calle, PhD, CMPP

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / CE

All You're Itching to Know About Atopic Dermatitis

Authors: Lawrence F. Eichenfield, MD; Jonathan I. Silverberg, MD, PhD, MPH; Emma Guttman-Yassky, MD, PhD; Eric L. Simpson, MD, MCR
CME / CE Released: 6/14/2021
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 6/14/2022

Start Activity

Target Audience and Goal Statement

This activity is intended for dermatologists, allergists/clinical immunologists, pediatricians, primary care physicians (PCPs), physician assistants (PAs), nurse practitioners (NPs), and nurses involved in the care of patients with atopic dermatitis (AD).

The goal of this activity is to present and discuss the most current evidence and practices in treating AD.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical data on new/emerging topical AD medications
- Clinical effect of investigational targeted systemic/biologic agents for AD
Have greater competence related to
- Integrating into practice treatments that target the inflammatory etiology of AD
- Selecting age-appropriate treatment based on AD severity
- Tailoring evidence-based AD therapies based on patient characteristics

Disclosures

Faculty

Lawrence F. Eichenfield, MD

Professor of Dermatology and Pediatrics
Vice Chair
Department of Dermatology
Chief
Pediatric and Adolescent Dermatology
University of California, San Diego
Rady Children's Hospital, San Diego
San Diego, California

Disclosures

Disclosure: Lawrence F. Eichenfield, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Almirall; Dermavant; Dermira Inc.; Eli Lilly and Company; Forte Biosciences; Galderma Laboratories, L.P.; Incyte Corporation; LEO Pharma; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme
Received grants for clinical research from: AbbVie Inc.; Regeneron Pharmaceuticals, Inc.; Ortho Dermatologics; Sanofi Genzyme
Owns stock, stock options, or bonds from: Forte Biosciences
Other: Asana Biosciences, LLC; Glenmark

Jonathan I. Silverberg, MD, PhD, MPH

Associate Professor
Department of Dermatology
Director
Clinical Research
Director
Patch Testing
The George Washington University School
of Medicine and Health Sciences
Washington, DC

Disclosures

Disclosure: Jonathan I. Silverberg, MD, PhD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AFYX; Arena Pharmaceuticals, Inc.; Asana Biosciences, LLC; BioMX; Bluefin; Bodewell; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; Dermira Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline; Incyte Corporation; Kiniksa; LEO Pharma; Luna; Menlo; Novartis Pharmaceuticals Corporation; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc; Sanofi
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Received grants for clinical research from: Galderma Laboratories, L.P.; Pfizer Inc.

Emma Guttman-Yassky, MD, PhD

Waldman Professor and System Chair, Dermatology
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York
President
International Eczema Council
Chicago, Illinois

Disclosures

Disclosure: Emma Guttman-Yassky, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Aditum Bio; Almirall; Amgen Inc.; Asana Biosciences, LLC; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Cara Therapeutics; Celgene Corporation; Concert; DBV; Dermira Inc.; DS Biopharma; Eli Lilly and Company; EMD Serono; Escalier; Galderma Laboratories, L.P.; Ichnos Sciences; Incyte Kyowa Kirin; LEO Pharma; Mitsubishi Tanabe; Pandion Therapeutics; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc.; Sanofi; Sienna Biopharma; Target PharmaSolutions; Union Therapeutics
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Almirall; Amgen Inc.; AnaptysBio; Asana Biosciences, LLC; Boehringer-Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; DS Biopharma; Eli Lilly and Company; Galderma Laboratories, L.P.; Ichnos Sciences; Innovaderm; Janssen Pharmaceuticals; Kiniksa; Kyowa Kirin; LEO Pharma; Novan; Pfizer Inc.; Ralexar; Regeneron Pharmaceuticals, Inc.; Sienna Biopharma; UCB Pharma, Inc.; Union Therapeutics

Eric L. Simpson, MD, MCR

Professor of Dermatology
Oregon Health & Science University
Portland, Oregon

Disclosures

Disclosure: Eric L. Simpson, MD, MCR, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Arena Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Collective Acumen LLC; Eli Lilly and Company; Forte Bio; Incyte Corporation; Janssen Pharmaceuticals; Kyowa Hakko Kirin; LEO Pharma; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Pfizer Inc.; Pierre Fabre Dermo Cosmetique; Regeneron Pharmaceuticals, Inc.; Roivant; Sanofi; Valeant Pharmaceuticals International
Received grants for clinical research from: AbbVie Inc.; Eli Lilly and Company; Kyowa Hakko Kirin; LEO Pharma; Merck; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi; Tioga; Vanda

Editor

Marinella Calle, PhD, CMPP

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For Nurses

Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Dermatology

CME / CE

All You're Itching to Know About Atopic Dermatitis

Authors: Lawrence F. Eichenfield, MD; Jonathan I. Silverberg, MD, PhD, MPH; Emma Guttman-Yassky, MD, PhD; Eric L. Simpson, MD, MCRFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / CE Released: 6/14/2021

Valid for credit through: 6/14/2022

processing....

Patient Handout for Adults With AD

Patient Handout for Children With AD

Contents of This CME Activity

All sections of this activity are required for credit.

The Evolving Pathogenesis of Atopic Dermatitis

Learn about the pathogenesis of atopic dermatitis.
Emma Guttman-Yassky, MD, PhD

Current Concepts in Targeted Oral and Topical Therapies for Atopic Dermatitis

Learn about latest developments with targeted oral and topical therapies in atopic dermatitis.
Jonathan I. Silverberg, MD, PhD, MPH

Biologics for Atopic Dermatitis: New and Emerging Agents

Join the expert faculty as he covers hot topics with biologics in atopic dermatitis.
Eric L. Simpson, MD, MCR

Pediatric Atopic Dermatitis: Infants and Beyond

Join the faculty update on treatments for pediatric patients with atopic dermatitis.
Lawrence F. Eichenfield, MD

Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 7

CME / CE Information Download Slides

PDF Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Lawrence F. Eichenfield, MD

Jonathan I. Silverberg, MD, PhD, MPH

Emma Guttman-Yassky, MD, PhD

Eric L. Simpson, MD, MCR

Editor

Marinella Calle, PhD, CMPP

CME Reviewer

Esther Nyarko, PharmD

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / CE

All You're Itching to Know About Atopic Dermatitis

Target Audience and Goal Statement

Disclosures

Faculty

Lawrence F. Eichenfield, MD

Jonathan I. Silverberg, MD, PhD, MPH

Emma Guttman-Yassky, MD, PhD

Eric L. Simpson, MD, MCR

Editor

Marinella Calle, PhD, CMPP

CME Reviewer

Esther Nyarko, PharmD

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

All You're Itching to Know About Atopic Dermatitis

Contents of This CME Activity

The Evolving Pathogenesis of Atopic Dermatitis

Current Concepts in Targeted Oral and Topical Therapies for Atopic Dermatitis

Biologics for Atopic Dermatitis: New and Emerging Agents

Pediatric Atopic Dermatitis: Infants and Beyond

Assessment Survey

PDF Downloads